
FDA clears IND application for melanoma treatment
The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma. The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint. Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre… Read More



